1. Edward P. Sloan, MD, MPH Case Studies in Cerebrovascular Emergencies Research:

2. Edward P. Sloan, MD, MPH Current International Clinical Trials in Ischemic and Hemorrhagic Stroke

3. Edward P. Sloan, MD, MPH SIMEU / ACEP Emergency Medicine Congress

4. Edward P. Sloan, MD, MPH Turino, Italy November 9-11, 2006

5. Edward P. Sloan, MD, MPH Edward P. Sloan, MD, MPH Professor Department of Emergency Medicine University of Illinois College of Medicine Chicago, IL

6. Edward P. Sloan, MD, MPH Attending Physician Emergency Medicine University of Illinois Hospital Our Lady of the Resurrection Hospital Chicago, IL

7. Edward P. Sloan, MD, MPH

8. Disclosures NovoNordisk, King Pharmaceuticals, UCB Pharma Advisory BoardsNovoNordisk, King Pharmaceuticals, UCB Pharma Advisory Boards Eisai Speakers’ BureauEisai Speakers’ Bureau ACEP Clinical Policies CommitteeACEP Clinical Policies Committee ACEP Scientific Review CommitteeACEP Scientific Review Committee Executive Board, FERNEExecutive Board, FERNE FERNE support by Abbott, Eisai, Pfizer, UCBFERNE support by Abbott, Eisai, Pfizer, UCB

9. Edward P. Sloan, MD, MPH Board Chairman and President FERNE Chicago, IL

10. Edward P. Sloan, MD, MPH www.ferne.org

11. William Barsan, MD FACEP Jonathan Edlow, MD, FACEP J. Stephen Huff, MD, FACEP Andrew Jagoda, MD, FACEP Our Italian hosts. A Special Welcome To…

12. Edward P. Sloan, MD, MPH Today’s Agenda Present the current clinical situationPresent the current clinical situation Review two articles and editorialsReview two articles and editorials Consider the research impactConsider the research impact Consider the clinical care impactConsider the clinical care impact Project future work and collaborationProject future work and collaboration

13. Edward P. Sloan, MD, MPH Clinical Cases

14. Edward P. Sloan, MD, MPH Ischemic Stroke Patient 67 year old male67 year old male Pt experiences L sided weaknessPt experiences L sided weakness Occurs during breakfastOccurs during breakfast Slurred speechSlurred speech Arrives by EMS to the ED in 30 minArrives by EMS to the ED in 30 min Accucheck 300Accucheck 300

15. Edward P. Sloan, MD, MPH Hemorrhagic Stroke Pt 58 year old female58 year old female Pt with a change in mental statusPt with a change in mental status Headache, not feeling wellHeadache, not feeling well Went back to bedWent back to bed Found by family less responsiveFound by family less responsive Arrives by EMS to the ED in 15 minArrives by EMS to the ED in 15 min Blood pressure 228/126Blood pressure 228/126

16. Edward P. Sloan, MD, MPH Learning Objectives and Key Clinical Questions

17. Edward P. Sloan, MD, MPH Session Objectives Discuss the impact of the negative SAINT II trial of NXY-059 on the development of an effective neuroprotectant for the treatment of ischemic stroke patients. Discuss the impact of the negative SAINT II trial of NXY-059 on the development of an effective neuroprotectant for the treatment of ischemic stroke patients. Review the current status of the clinical trials of Factor VIIa in the treatment of intracerebral hemorrhage and the differences between these clinical trials and those of NXY-059. Review the current status of the clinical trials of Factor VIIa in the treatment of intracerebral hemorrhage and the differences between these clinical trials and those of NXY-059.

18. Edward P. Sloan, MD, MPH Session Objectives Determine how the data from these large international trials can improve the care of acute stroke patients even if the results of the clinical trials do not identify a new effective therapy. Determine how the data from these large international trials can improve the care of acute stroke patients even if the results of the clinical trials do not identify a new effective therapy. Consider how the NETT research consortium might enhance CNS emergencies clinical trials research in the US and internationally. Consider how the NETT research consortium might enhance CNS emergencies clinical trials research in the US and internationally.

19. Edward P. Sloan, MD, MPH Key Clinical Questions What can be learned from the international clinical trials of NXY- 059 and Factor VIIa regarding neurological emergencies clinical trial design and conduct? What can be learned from the international clinical trials of NXY- 059 and Factor VIIa regarding neurological emergencies clinical trial design and conduct?

20. Edward P. Sloan, MD, MPH Key Clinical Questions How can the data from these clinical trials be successfully analyzed so that the story can be told of how acute ischemic and hemorrhagic stroke patients can be optimally managed in the 21st century, especially in the area of tPA use in ischemic stroke? How can the data from these clinical trials be successfully analyzed so that the story can be told of how acute ischemic and hemorrhagic stroke patients can be optimally managed in the 21st century, especially in the area of tPA use in ischemic stroke?

21. Edward P. Sloan, MD, MPH Key Clinical Questions How can the formation of NETT in the US be leveraged to enhance international research and collaboration in the area of acute neurological emergencies patient management? How can the formation of NETT in the US be leveraged to enhance international research and collaboration in the area of acute neurological emergencies patient management?

22. Edward P. Sloan, MD, MPH Key Clinical Questions What are the best next steps to be taken be leaders in the field of neurological emergencies research, patient management, clinical trials design, clinical policy formation, patient advocacy, and public health? What are the best next steps to be taken be leaders in the field of neurological emergencies research, patient management, clinical trials design, clinical policy formation, patient advocacy, and public health?

23. Edward P. Sloan, MD, MPH NXY-059: Clinical and Research Data

24. Edward P. Sloan, MD, MPH NXY-059 Clinical Data Neuroprotectant Neuroprotectant Remains intravascular Remains intravascular Does not cross blood brain barrier Does not cross blood brain barrier Protects neurons Protects neurons

25. Edward P. Sloan, MD, MPH NXY-059 Research Data SAINT I positive phase III trial SAINT I positive phase III trial 1722 patients 1722 patients Improved outcome using mRS Improved outcome using mRS Reduced tPA significant ICH rate Reduced tPA significant ICH rate SAINT II confirmatory trial: 3000 pts SAINT II confirmatory trial: 3000 pts SAINT II phase III trial negative SAINT II phase III trial negative

26. Edward P. Sloan, MD, MPH NXY-059 Publications NEJM Feb 2006 article NEJM Feb 2006 article Lees et al Lees et al Multinational phase III clinical trial Multinational phase III clinical trial NEJM Feb 2006 editorial NEJM Feb 2006 editorial del Zoppo del Zoppo “Stroke & Neurovascular Protection” “Stroke & Neurovascular Protection”

27. Edward P. Sloan, MD, MPH Key Clinical Questions Clinical trials often will generate different results given differences in patient populations and standard therapies. Clinical trials often will generate different results given differences in patient populations and standard therapies. What should be done if one trial is positive and the other neutral? What should be done if one trial is positive and the other neutral?

28. Edward P. Sloan, MD, MPH Key Clinical Questions The FDA requries paired phase III clinical trials in order for efficacy to be demonstrated. The FDA requries paired phase III clinical trials in order for efficacy to be demonstrated. Should paired trials be required for all drugs in development? Should paired trials be required for all drugs in development?

29. Edward P. Sloan, MD, MPH Key Clinical Questions What is a possible explanation of these two clinical trials not having the same results? What is a possible explanation of these two clinical trials not having the same results?

30. Edward P. Sloan, MD, MPH Key Clinical Questions Emergency physicians utilize many therapies that provide neuroprotection: airway, blood pressure, and ICP/cerebral perfusion control being the most important. Emergency physicians utilize many therapies that provide neuroprotection: airway, blood pressure, and ICP/cerebral perfusion control being the most important. Is neuroprotection possible using a specific neuroprotectant? Is neuroprotection possible using a specific neuroprotectant?

31. Edward P. Sloan, MD, MPH Key Clinical Questions The proposed number needed to treat in the SAINT I trial was approximately 24. The proposed number needed to treat in the SAINT I trial was approximately 24. The NNT in the tPA clinical trials was approximately 8. The NNT in the tPA clinical trials was approximately 8. What does this suggest about the efficacy of IV tPA in ischemic stroke? What does this suggest about the efficacy of IV tPA in ischemic stroke?

32. Edward P. Sloan, MD, MPH Factor VIIa: Clinical and Research Data

33. Edward P. Sloan, MD, MPH Factor VIIa Clinical Data Anticoagulant Anticoagulant Final common pathway agent Final common pathway agent Used to treat hemophilia patients Used to treat hemophilia patients Reduces hemorrhage volume in ICH patients volume via hemostasis Reduces hemorrhage volume in ICH patients volume via hemostasis

34. Edward P. Sloan, MD, MPH Factor VIIa Research Data Positive phase III trial Positive phase III trial 399 patients 399 patients Reduced hemorrhage volume Reduced hemorrhage volume Improved outcome using mRS Improved outcome using mRS Increased thromboembolic events Increased thromboembolic events Confirmatory trial taking place Confirmatory trial taking place

35. Edward P. Sloan, MD, MPH Factor VIIa Publications NEJM Feb 2005 article NEJM Feb 2005 article Mayer et al Mayer et al Multinational phase III clinical trial Multinational phase III clinical trial NEJM Feb 2006 editorial NEJM Feb 2006 editorial Brown and Morgenstern Brown and Morgenstern “Stopping the Bleeding in ICH” “Stopping the Bleeding in ICH”

36. Edward P. Sloan, MD, MPH Key Clinical Questions What is the number needed to treat with this therapy in order to provided the best clinical outcome? What is the number needed to treat with this therapy in order to provided the best clinical outcome?

37. Edward P. Sloan, MD, MPH Key Clinical Questions What can be learned about the use of the modified Rankin Scale in the clinical trials and treatement of stroke patients? What can be learned about the use of the modified Rankin Scale in the clinical trials and treatement of stroke patients?

38. Edward P. Sloan, MD, MPH Key Clinical Questions This drug is already FDA approved and can and is already being used by clinicians for ICH patients. This drug is already FDA approved and can and is already being used by clinicians for ICH patients. How can this situation be optimally managed? How can this situation be optimally managed?

39. Edward P. Sloan, MD, MPH Key Clinical Questions What will happen if the second confirmatory trial is neutral and clinicians alraedy are used to including this therapy in the management of ICH patients? What will happen if the second confirmatory trial is neutral and clinicians alraedy are used to including this therapy in the management of ICH patients?

40. Edward P. Sloan, MD, MPH Clinical Trials Data: Providing Maximal Benefit

41. Edward P. Sloan, MD, MPH Key Clinical Questions How can we best access and publish data from industry sponsored clinical trials? How can we best access and publish data from industry sponsored clinical trials?

42. Edward P. Sloan, MD, MPH Key Clinical Questions What might be learned from the tPA data contained within the NXY-059 clinical trials, especially with regards to tPA use in the ED? What might be learned from the tPA data contained within the NXY-059 clinical trials, especially with regards to tPA use in the ED?

43. Edward P. Sloan, MD, MPH Key Clinical Questions What might be learned about the clinical practice of Emergemcy Medicine and the resuscitation of acute stroke patients from these clinical trials? What might be learned about the clinical practice of Emergemcy Medicine and the resuscitation of acute stroke patients from these clinical trials?

44. Edward P. Sloan, MD, MPH Key Clinical Questions What can be learned about outcome measures such as the modified Rankin Scale and their use in clinical trials research? What can be learned about outcome measures such as the modified Rankin Scale and their use in clinical trials research?

45. Edward P. Sloan, MD, MPH Coordinated Research & NETT: How Can This Opportunity Be Leveraged Internationally?

46. Edward P. Sloan, MD, MPH Key Clinical Questions How can the detailed clinical trials conducted by industry be performed by NETT? How can the detailed clinical trials conducted by industry be performed by NETT?

47. Edward P. Sloan, MD, MPH Key Clinical Questions What role for NETT is envisioned for the development of clinical trials that answer important stroke patient care questions? What role for NETT is envisioned for the development of clinical trials that answer important stroke patient care questions?

48. Edward P. Sloan, MD, MPH Key Clinical Questions Could a reserch network such as NETT be developed in Italy in order to enhance clinical care, research, and the specialty of Emergency Medicine? Could a reserch network such as NETT be developed in Italy in order to enhance clinical care, research, and the specialty of Emergency Medicine?

49. Edward P. Sloan, MD, MPH Key Clinical Questions Could a reserch network such as NETT be developed in the EU in order to enhance clinical care, research, and the specialty of Emergency Medicine? Could a reserch network such as NETT be developed in the EU in order to enhance clinical care, research, and the specialty of Emergency Medicine?

50. Edward P. Sloan, MD, MPHConclusions Important neurological emergencies research being conducted by industry Much can be learned from these protocols and the patients treated in the context of this clinical trials research It is an opportunity for emergency physicians to better understand our clinical practice Opportunities for international work exist

51. Edward P. Sloan, MD, MPHRecommendations We should closely monitor the outcomes of these clinical trials A concerted effort to analyze all aspects of these clinical trials should be made Collaboration with industry and government should be enhanced Examination of opportunities abroad should be made

52. Edward P. Sloan, MD, MPH Questions? www.FERNE.org edsloan@uic.edu 312 413 7490 ferne_simeu_2006_sloan_neuroprotection_111006_final 9/15/2015 9:54 PM (11/10 1126 am)